Hamilton, On; Robert Levy, Vancouver, BC; Francois Maltais,
Montreal, Que; Denis O’Donnell, Kingston, On.
Czech Republic: Jan Krepelka, Praha.
Denmark: JØrgen Vestbo, Hvidovre.
Netherlands: Emiel Wouters, Horn-Maastricht.
New Zealand: Dean Quinn, Wellington.
Norway: Per Bakke, Bergen.
Slovenia: Mitja Kosnik, Golnik.
Spain: Alvar Agusti, Jaume Sauleda, Palma de Mallorca.
Ukraine: Yuri Feschenko, Kiev; Vladamir Gavrisyuk,
Kiev; Lyudmila Yashina, Kiev; Nadezhda Monogarova,
Donetsk.
United Kingdom: Peter Calverley, Liverpool; David Lomas, Cambridge; William MacNee, Edinburgh; David Singh,
Manchester; Jadwiga Wedzicha, London.
United States of America: Antonio Anzueto, San Antonio, TX; Sidney Braman, Providence, RI; Richard Casaburi,
Torrance CA; Bart Celli, Boston, MA; Glenn Giessel, Richmond, VA; Mark Gotfried, Phoenix, AZ; Gary Greenwald,
Rancho Mirage, CA; Nicola Hanania, Houston, TX; Don
Mahler, Lebanon, NH; Barry Make, Denver, CO; Stephen
Rennard, Omaha, NE; Carolyn Rochester, New Haven, CT;
Paul Scanlon, Rochester, MN; Dan Schuller, Omaha, NE;
Frank Sciurba, Pittsburgh, PA; Amir Sharafkhaneh, Houston, TX; Thomas Siler, St. Charles, MO, Edwin Silverman,
Boston, MA; Adam Wanner, Miami, FL; Robert Wise, Baltimore, MD; Richard Zu Wallack, Hartford, CT.
Steering Committee: Harvey Coxson (Canada), Lisa Edwards (GlaxoSmithKline, USA), Katharine Knobil (Co-chair,
GlaxoSmithKline, UK), David Lomas (UK), William MacNee (UK), Edwin Silverman (USA), Ruth Tal-Singer (
GlaxoSmithKline, USA), Jørgen Vestbo (Co-chair, Denmark), Julie
Yates (GlaxoSmithKline, USA).
Scientific Committee: Alvar Agusti (Spain), Peter Calverley (UK), Bartolome Celli (USA), Courtney Crim (
GlaxoSmithKline, USA), Gerry Hagan (GlaxoSmithKline, UK),
William MacNee (Chair, UK), Stephen Rennard (USA), Ruth
Tal-Singer (GlaxoSmithKline, USA), Emiel Wouters (The
Netherlands), Julie Yates (GlaxoSmithKline, USA).
REFERENCES
1. Rust K, Grosso L, Zhang V, Chang D, Persson A, Longmore W,
Cai GZ, Crouch E. Human surfactant protein D: SP-D contains
a C-type lectin carbohydrate recognition domain. Arch Biochem
Biophys 1991; 290(1): 116–126.
2. Crouch E, Rust K, Marienchek W, Parghi D, Chang D, Persson
A. Developmental expression of pulmonary surfactant protein D
(SP-D). Am J Respir Cell Mol Biol 1991; 5(1):13–18.
3. Hartshorn K, Chang D, Rust K, White M, Heuser J. Crouch E.
Interactions of recombinant human pulmonary surfactant protein
D and SP-D multimers with influenza A. Am J Physiol 1996; 271(5
Pt 1): L753–762.
4. Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and
lipoarabinomannan via carbohydrate-lectin interactions resulting
in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999; 163(1):312–321.
5. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt
A, Tauber B, Shepherd V, Sastry KN. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol
1998; 274(6 Pt 1):L958–969.
6. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK,
Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE. Role
of surfactant proteins A, D, and C1q in the clearance of apoptotic
cells in vivo and in vitro: Calreticulin and CD91 as a common
collectin receptor complex. J Immunol 2002; 169(7):3978–3986.
7. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher
LJ. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol
1998; 161(9):4599–4603.
8. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH,
Kim KS, McCormack FX. Surfactant proteins A and D inhibit the
growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111(10):1589–1602.
9. Strong P, Reid KB, Clark H. Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic
hypersensitivity in mice sensitized to allergens of Aspergillus fu-migatus. Clin Exp Immunol 2002; 130(1):19–24.
10. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary
host defense. Annu Rev Physiol 2001; 63:521–554.
11. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene
KE, Henson PM. By binding SIRPalpha or calreticulin/CD91, lung
collectins act as dual function surveillance molecules to suppress
or enhance inflammation. Cell 2003; 115(1):13–23.
12. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid
KB. Nucleic acid is a novel ligand for innate, immune pattern
recognition collectins surfactant proteins A and D and mannose-binding lectin. J Biol Chem 2004; 279(31):32728–32736.
13. Knudsen L, Ochs M, Mackay R, Townsend P, Deb R, Muhlfeld
C, Richter J, Gilbert F, Hawgood S, Reid K, Clark H. Truncated
recombinant human SP-D attenuates emphysema and type II cell
changes in SP-D deficient mice. Respir Res 2007; 8: 70.
14. Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A,
Koch C, Teisner B, Junker P, Holmskov U. Surfactant protein D
(SP-D) serum levels in patients with community-acquired pneumonia small star, filled. Clin Immunol 2003; 108(1):29–37.
15. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, Ka-sukawa R, Suzuki S. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in
rheumatoid arthritis. Intern Med 2002; 41(6):467–473.
16. Umetani K, Abe M, Kawabata K, Iida T, Kohno I, Sawanobori
T, Kugiyama K. SP-D as a marker of amiodarone-induced pulmonary toxicity. Intern Med 2002; 41(9):709–712.
17. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura
K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant
protein-A, surfactant protein-D, and monocyte chemoattractant
protein-1 as serum markers for interstitial lung diseases. Am J
Respir Crit Care Med 2002; 165(3):378–381.
18. Krane M, Griese M. Surfactant protein D in serum from patients
with allergic bronchopulmonary aspergillosis. Eur Respir J 2003;
22(4):592–595.
19. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF,
Panettieri RA, Haczku A. Chronic obstructive pulmonary disease
and inhaled steroids alter surfactant protein D (SP-D) levels: a
cross-sectional study. Respir Res 2008; 9:13.
20. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller
BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is
steroid sensitive and associated with exacerbations of COPD. Eur
Respir J 2009; 34(1): 95–102.
21. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong
E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie
RL, Williams D, Gan WQ, Rousseau R. The effects of fluticasone
with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2008; 177(11):1207–1214.
22. Cooley J, McDonald B, Accurso FJ, Crouch EC, Remold-O’Donnell E. Patterns of neutrophil serine protease-dependent
cleavage of surfactant protein D in inflammatory lung disease. J
Leukoc Biol 2008; 83(4):946–955.
23. Duvoix A, Mackay RM, Henderson N, McGreal E, Postle A,
Reid K, Clark H. Physiological concentration of calcium inhibits
